Han Wonshik, Kang Daehee, Lee Jong Eun, Park In Ae, Choi Ji-Yeob, Lee Kyung-Mu, Bae Ji Yeon, Kim Sook, Shin Eun-Soon, Lee Jeong Eon, Shin Hyuk-Jae, Kim Seok Won, Kim Sung-Won, Noh Dong-Young
Department of Surgery, Seoul National University College of Medicine, and DNA Link Inc., Seoul, Korea.
Clin Cancer Res. 2005 Jul 1;11(13):4775-8. doi: 10.1158/1078-0432.CCR-04-2208.
A single-nucleotide polymorphism (SNP) in codon 655 of HER-2 has been extensively studied with inconclusive results. The purpose of this study was to investigate the association between common variants of HER-2 and breast cancer risk, HER-2 expression, and survival using a haplotype-based stepwise approach.
Twenty-nine SNPs listed in the National Center for Biotechnology Information database were screened to identify novel polymorphisms of HER-2 gene in 90 healthy Korean women. Six of 29 SNPs were polymorphic and had greater than 10% of minor allele frequencies. Using these six SNPs, linkage disequilibrium and haplotype patterns were characterized. We tested association between the haplotypes and breast cancer in a large case-control study (n=1,039 cases and 995 controls). Six-hundred two breast cancer patients with follow-up at least 24 months were analyzed for outcome in relation to haplotype. Expression of HER-2 protein was determined by immunohistochemistry in 1,094 cases of invasive breast cancer.
All six SNPs showed a strong linkage disequilibrium pattern and were considered to belong to one haplotype block. Two haplotype-tagging SNPs (I655V and P1170A) for three common haplotypes (>5%) were genotyped in cases and controls. The haplotypes and individual SNPs were not associated with breast cancer risk. In patients with at least one copy of haplotype I (the most common haplotype), HER-2 expression was 1.5 times higher (P = 0.009) and the prognosis was worse (P = 0.032) compared with patients without having that haplotype.
Our results suggest that the currently identified genetic polymorphisms of HER-2 are not associated with an increased risk of breast cancer in Korean women, whereas one haplotype does affect protein expression of the tumor and disease outcome.
对HER-2基因655密码子处的单核苷酸多态性(SNP)已进行了广泛研究,但结果尚无定论。本研究旨在采用基于单倍型的逐步分析方法,探讨HER-2常见变异与乳腺癌风险、HER-2表达及生存之间的关联。
对美国国立生物技术信息中心数据库中列出的29个SNP进行筛选,以鉴定90名健康韩国女性中HER-2基因的新型多态性。29个SNP中有6个具有多态性,且次要等位基因频率大于10%。利用这6个SNP,对连锁不平衡和单倍型模式进行了表征。我们在一项大型病例对照研究(1039例病例和995例对照)中测试了单倍型与乳腺癌之间的关联。对602例随访至少24个月的乳腺癌患者进行了单倍型相关结局分析。采用免疫组织化学法测定了1094例浸润性乳腺癌病例中HER-2蛋白的表达。
所有6个SNP均显示出强烈的连锁不平衡模式,被认为属于一个单倍型块。对三种常见单倍型(>5%)的两个单倍型标签SNP(I655V和P1170A)在病例组和对照组中进行基因分型。单倍型和单个SNP与乳腺癌风险无关。与没有该单倍型的患者相比,至少有一份单倍型I(最常见的单倍型)的患者,HER-2表达高1.5倍(P = 0.009),预后更差(P = 0.032)。
我们的结果表明,目前鉴定出的HER-2基因多态性与韩国女性乳腺癌风险增加无关,而一种单倍型确实会影响肿瘤的蛋白表达和疾病结局。